This site is intended for healthcare professionals
Drug information

Esomeprazole

POM
Read time: 23 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Esomeprazole 20mg tablets are indicated in adults for:

Gastro-oesophageal Reflux Disease (GERD)

- treatment of erosive reflux oesophagitis

- long-term management of patients with healed oesophagitis to prevent relapse

- symptomatic treatment of gastro-oesophageal reflux disease (GERD).

In combination with appropriate antibacterial therapeutic regimens for the eradication of

Helicobacter pylori

and

- healing of Helicobacter pylori associated duodenal ulcer and

- prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers.

Patients requiring continued NSAID therapy

- healing of gastric ulcers associated with NSAID therapy.

- prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.

Treatment of Zollinger Ellison Syndrome.

Esomeprazole 20mg tablets are indicated in adolescents from the age of 12 years for:

Gastro-oesophageal Reflux Disease (GERD)

- treatment of erosive reflux oesophagitis

- long-term management of patients with healed oesophagitis to prevent relapse

- symptomatic treatment of gastro-oesophageal reflux disease (GERD)

In combination with antibiotics in treatment of duodenal ulcer caused by

Helicobacter pylori.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).